


BCR::ABL1 ordering guide



BCR::ABL1 ORDERING GUIDE FOR BLOOD AND BONE MARROW

INDICATION	MAYO ID	TEST NAME	APPROPRIATE ORDERING SCENARIO
Diagnostic evaluation - Confirm suspected new CML. - Rule out possible CML. - Evaluate for <i>BCR::ABL1</i> in B-ALL.	BADX	<i>BCR::ABL1</i> , Qualitative, Diagnostic Assay, Varies	- Identification of presence and fusion type of <i>BCR::ABL1</i> transcript in a diagnostic sample. - Detects common <i>BCR::ABL1</i> fusion types (p210, p190). - Detects rare <i>BCR::ABL1</i> fusion types. - Qualitative assay (no information on <i>BCR::ABL1</i> level provided). - Establishes precise fusion type for future measurable disease tracking.
	BCRFX	<i>BCR::ABL1</i> Qualitative Diagnostic Assay with Reflex to <i>BCR::ABL1</i> p190 Quantitative Assay or <i>BCR::ABL1</i> p210 Quantitative Assay, Varies	- BADX-positive case is reflexed to additional testing to provide an initial (diagnostic) level of <i>BCR::ABL1</i> fusion transcript, specifically p210 and p190 types. - A quantitative value for the detected fusion type (p210 or p190) will be provided for precise future measurable disease tracking.
Disease monitoring (follow-up post-therapy), measurable residual disease (MRD) detection	BCRAB	<i>BCR::ABL1</i> , p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies	- p210 (e13e14/a2) specific fusion type monitoring (MRD). - Quantitative results provided.
	BA190	<i>BCR::ABL1</i> , p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies	- p190 (e1/a2) specific fusion type monitoring (MRD). - Quantitative results provided.
Note: requires knowledge of specific <i>BCR::ABL1</i> fusion type identified by diagnostic testing above	BARQ	<i>BCR::ABL1</i> , Rare Fusion Monitoring, Quantitative, Varies	- Rare <i>BCR::ABL1</i> fusion type monitoring (MRD) for non-p210 or non- p190 transcript types. - Quantitative results provided.
Therapeutic resistance analysis (<i>BCR::ABL1</i> inhibitor resistance)	BAKDM	<i>BCR::ABL1</i> , Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing, Varies	- Identifies somatic mutations in the kinase domain of <i>BCR::ABL1</i> associated with acquired resistance to tyrosine kinase inhibitors and related agents. - Qualitative result provided; specific mutation(s) and significance reported, if present.

MC2775-598rev0926